The Prevalence of Fibromyalgia in Adults at Al-Karak Jordan a Cross-sectional Study

Fibromyalgia is a chronic and intricate musculoskeletal disorder characterized by widespread pain, fatigue, and tenderness in specific anatomical regions. Although its prevalence varies among populations, understanding the prevalence in different geographical areas is crucial for healthcare planning. This cross-sectional study aims to determine the prevalence of fibromyalgia in adults residing in Al-Karak, Jordan. The city's unique demographic and environmental characteristics may influence the occurrence of fibromyalgia among its adult population. The study aims to address gaps in knowledge, provide localized insights, and shed light on fibromyalgia's burden on the community's health. Accurate prevalence data aids healthcare planning and resource allocation.

Study Overview

• Status: Recruiting
• Conditions: Fibromyalgia; Orthopedic Disorder
• Intervention / Treatment: Other: Cross sectional

• Study Type: Observational
• Enrollment (Estimated): 965

Contacts and Locations

• Study Contact: Name: Mohammad Abu-Jeyyab, MD; Phone Number: +962796383747; Email: mabujeyyab@yahoo.com
• Study Contact Backup: Name: Alaa Akel, MD; Phone Number: 0796383747; Email: alaaakel@mutah.edu.jo

Study Locations

• Jordan
  • Al-Karak, Jordan, 61710
    • Recruiting
    • Mutah University
    • Contact: Mutah University; Phone Number: 0796383747; Email: mabujeyyab@yahoo.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

The study found a 26.5% prevalence of fibromyalgia in the studied population. Female gender, mental health illnesses, and comorbidities like irritable bowel syndrome, psychiatric disorders, and rheumatological and neurological diseases were significantly associated with fibromyalgia. Age, BMI, marital status, employment status, and certain comorbidities did not show statistically significant predictive value.

Discussion: The significant prevalence of fibromyalgia and its links to female gender, mental health problems, and comorbidities highlight the necessity for specific healthcare interventions and public awareness initiatives. The study's findings help to understand the imp

Description

Using google forms, this cross-sectional study was carried out, and the participants were reached via social media platforms (5)

. Participants' autonomy was maintained, and no direct benefit was gained in return for filling out the questionnaire. The ethics committee at the Faculty of Medicine, Mutah University, Karak, Jordan, provided the required ethical approval prior to the initiation of this study. Moreover, the committee ensured that the study was designed according to the principles of the Declaration of Helsinki (Date: 13 February 2023. Reference number: 992023). In this study, the authors targeted Karak government citizens, in Jordan. Accordingly, the required sample size to achieve a 99% Confidence interval was 663 participants.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Positive for fibromyalgia; 26.5% prevalence of fibromyalgia
Negative for fibromyalgia; 26.5% prevalence of fibromyalgia	Other: Cross sectional; Cross sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cross sectional	Outcome measurements	2 years

Collaborators and Investigators

• Sponsor: Mutah University

Study record dates

Study Major Dates

• Study Start (Actual): May 12, 2023
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: October 22, 2023
• First Submitted That Met QC Criteria: October 22, 2023
• First Posted (Actual): October 26, 2023

Study Record Updates

• Last Update Posted (Actual): October 26, 2023
• Last Update Submitted That Met QC Criteria: October 22, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Rheumatic Diseases; Muscular Diseases; Neuromuscular Diseases; Fibromyalgia; Myofascial Pain Syndromes; Musculoskeletal Diseases
• Other Study ID Numbers: 20235012

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No